The stock of Gilead Sciences, Inc (NASDAQ:GILD) last traded at $109.95, down -0.07% from the previous session.
GILD stock price is now 15.52% away from the 50-day moving average and 33.78% away from the 200-day moving average. The market capitalization of the company currently stands at $137.03B.
With the price target maintained at $120, Deutsche Bank recently Upgraded its rating from Hold to Buy for Gilead Sciences, Inc (NASDAQ: GILD). On February 13, 2025, DZ Bank Upgraded its previous ‘Hold’ rating to ‘Buy’ on the stock keeping its target price maintained at $108, while ‘Morgan Stanley’ rates the stock as ‘Overweight’
In other news, GILEAD SCIENCES, INC., 10% Owner bought 1,363,636 shares of the company’s stock on Feb 18 ’25. The stock was bought for $14,999,996 at an average price of $11.00. Upon completion of the transaction, the 10% Owner now directly owns 31,424,760 shares in the company, valued at $3.46 billion. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 18 ’25, Chief Financial Officer Dickinson Andrew D sold 2,500 shares of the business’s stock. A total of $260,225 was realized by selling the stock at an average price of $104.09. This leaves the insider owning 169,061 shares of the company worth $18.59 million. A total of 0.21% of the company’s stock is owned by insiders.
During the past 12 months, Gilead Sciences, Inc has had a low of $62.07 and a high of $110.11. As of last week, the company has a debt-to-equity ratio of 1.21, a current ratio of 1.50, and a quick ratio of 1.20.
The net profit margin was 1.67% and return on equity was 2.28% for GILD. The company reported revenue of $7.57 billion for the quarter, compared to $7.11 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 6.4 percent.
